Satish Boedhoe

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections.

An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections.

Journal: Clinical & translational immunology

Published: September 29, 2025

Heterologous vaccination with a next-generation vaccinia virus and Ad26 induces Ebola-specific immunity in macaques.

Heterologous vaccination with a next-generation vaccinia virus and Ad26 induces Ebola-specific immunity in macaques.

Journal: NPJ vaccines

Published: September 26, 2025

A self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naïve non-human primates.

A self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naïve non-human primates.

Journal: Nature communications

Published: June 18, 2024

The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia.

The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia.

Journal: Vaccines

Published: March 15, 2024

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets.

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets.

Journal: NPJ vaccines

Published: June 09, 2022

Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product Development.

Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product Development.

Journal: Journal of virology

Published: September 01, 2021

Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses.

Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses.

Journal: Vaccine

Published: March 09, 2018

Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.

Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.

Journal: International journal of cancer

Published: June 14, 2016

Showing 1-8 of 8

Last Updated: 09/26/2026